
## Yoon Soo Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8779722/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Involvement of aquaporins in colorectal carcinogenesis. Oncogene, 2003, 22, 6699-6703.	2.6	175
2	Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clinical Cancer Research, 2002, 8, 3669-75.	3.2	111
3	Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer, 2005, 104, 2753-2758.	2.0	98
4	Compound <i>EGFR</i> mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biology and Therapy, 2016, 17, 237-245.	1.5	92
5	MYC expression correlates with PD-L1 expression in non-small cell lung cancer. Lung Cancer, 2017, 110, 63-67.	0.9	86
6	Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clinical Cancer Research, 2002, 8, 3796-802.	3.2	78
7	Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer, 2007, 57, 373-380.	0.9	77
8	Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene, 2004, 23, 6569-6580.	2.6	63
9	Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clinical Cancer Research, 2003, 9, 3641-4.	3.2	58
10	The Clinical Utility of Polymerase Chain Reaction for the Diagnosis of Pleural Tuberculosis. Clinical Infectious Diseases, 2005, 41, 660-666.	2.9	46
11	Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma. Tuberculosis and Respiratory Diseases, 2016, 79, 248.	0.7	41
12	Lipid raft modulation inhibits NSCLC cell migration through delocalization of the focal adhesion complex. Lung Cancer, 2010, 69, 165-171.	0.9	38
13	Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Infection. Yonsei Medical Journal, 2012, 53, 974.	0.9	38
14	Promoter â^'202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk. International Journal of Cancer, 2006, 118, 353-356.	2.3	32
15	Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer. BMC Cancer, 2017, 17, 467.	1.1	32
16	Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma. BMC Cancer, 2016, 16, 27.	1.1	30
17	The Prevalence of Human Papillomavirus Infection in Korean Non-Small Cell Lung Cancer Patients. Yonsei Medical Journal, 2007, 48, 69.	0.9	28
18	Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis. Korean Journal of Internal Medicine, 2008, 23, 116.	0.7	28

#	Article	IF	CITATIONS
19	Inhibition of mTORC1 induces loss of E-cadherin through AKT/CSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells. Respiratory Research, 2014, 15, 26.	1.4	27
20	ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer. Neoplasia, 2017, 19, 354-363.	2.3	27
21	Fiberoptic bronchoscopy for the rapid diagnosis of smear-negative pulmonary tuberculosis. BMC Infectious Diseases, 2012, 12, 141.	1.3	26
22	Surgical decortication as the first-line treatment for pleural empyema. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 933-939.e1.	0.4	25
23	Keratinization of Lung Squamous Cell Carcinoma Is Associated with Poor Clinical Outcome. Tuberculosis and Respiratory Diseases, 2017, 80, 179.	0.7	25
24	Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16 <sup>INK4a</sup> -Negative Cancer. ACS Pharmacology and Translational Science, 2018, 1, 21-31.	2.5	25
25	Anastomotic Airway Complications after Lung Transplantation. Yonsei Medical Journal, 2015, 56, 1372.	0.9	23
26	Insulin-like growth factor-1 attenuates cisplatin-induced γH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer. Cancer Letters, 2008, 272, 232-241.	3.2	21
27	The feasibility of CT lung volume as a surrogate marker of donor–recipient size matching in lung transplantation. Medicine (United States), 2016, 95, e3957.	0.4	19
28	Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. Journal of Cancer, 2018, 9, 1113-1120.	1.2	18
29	Prediction model for hyperprogressive disease in nonâ€small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer, 2020, 11, 2793-2803.	0.8	18
30	Notch1 destabilizes the adherens junction complex through upregulation of the Snail family of E-cadherin repressors in non-small cell lung cancer. Oncology Reports, 2013, 30, 1423-1429.	1.2	17
31	Ratio of Autoantibodies of Tumor Suppressor AIMP2 and Its Oncogenic Variant Is Associated with Clinical Outcome in Lung Cancer. Journal of Cancer, 2017, 8, 1347-1354.	1.2	17
32	Retinoic Acid Receptor-β Expression in Stage I Non-Small Cell Lung Cancer and Adjacent Normal Appearing Bronchial Epithelium. Yonsei Medical Journal, 2004, 45, 435.	0.9	16
33	AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models. Cancer Letters, 2015, 358, 85-91.	3.2	16
34	Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984679.	1.4	16
35	Associations of Moderate to Severe Asthma with Obstructive Sleep Apnea. Yonsei Medical Journal, 2013, 54, 942.	0.9	15
36	Recent advances in diagnostic technologies in lung cancer. Korean Journal of Internal Medicine, 2020, 35, 257-268.	0.7	15

#	Article	IF	CITATIONS
37	Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on <i>EGFR</i> Mutation–Positive Lung Adenocarcinoma. Tuberculosis and Respiratory Diseases, 2020, 83, 51.	0.7	13
38	Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced nonâ€smallâ€cell lung cancer harboring EGFR mutations: Results from a realâ€world study in South Korea. Cancer Medicine, 2021, 10, 5809-5822.	1.3	13
39	KRAS oncogene substitutions in Korean NSCLC patients: Clinical implication and relationship with pAKT and RalGTPases expression. Lung Cancer, 2014, 85, 299-305.	0.9	12
40	Diagnostic utility of interferon-gamma release assay in extrapulmonary tuberculosis. Diagnostic Microbiology and Infectious Disease, 2015, 82, 44-48.	0.8	12
41	Effects of blood lead levels on airflow limitations in Korean adults: Findings from the 5th KNHNES 2011. Environmental Research, 2015, 136, 274-279.	3.7	12
42	Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer. Respiratory Research, 2020, 21, 142.	1.4	12
43	Brain Metastases From Lung Adenocarcinoma May Preferentially Involve the Distal Middle Cerebral Artery Territory and Cerebellum. Frontiers in Oncology, 2020, 10, 1664.	1.3	11
44	Effects of 9-cis-Retinoic Acid on the Insulin-Like Growth Factor Axis in Former Smokers. Journal of Clinical Oncology, 2005, 23, 4439-4449.	0.8	10
45	Late Respiratory Infection after Lung Transplantation. Tuberculosis and Respiratory Diseases, 2013, 74, 63.	0.7	10
46	Efficacy of Surgical Treatment for Brain Metastasis in Patients with Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2015, 56, 103.	0.9	10
47	BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis. Lung Cancer, 2015, 90, 106-110.	0.9	10
48	Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma. BMC Cancer, 2018, 18, 1221.	1.1	10
49	Methionyl-tRNA Synthetase is a Useful Diagnostic Marker for Lymph Node Metastasis in Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2019, 60, 1005.	0.9	10
50	Overexpression of CEACAM6 activates Src-FAK signaling and inhibits anoikis, through homophilic interactions in lung adenocarcinomas. Translational Oncology, 2022, 20, 101402.	1.7	10
51	9-cis retinoic acid induces insulin-like growth factor binding protein-3 through DR-8 Retinoic acid responsive elements. Cancer Biology and Therapy, 2006, 5, 586-592.	1.5	9
52	A Case of Locally Advanced Well-Differentiated Fetal Adenocarcinoma of the Lung Treated with Concurrent Chemoradiation Therapy. Tuberculosis and Respiratory Diseases, 2013, 74, 226.	0.7	9
53	Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma. Thoracic Cancer, 2019, 10, 2267-2273.	0.8	9
54	The repeatability of computed tomography lung volume measurements: Comparisons in healthy subjects, patients with obstructive lung disease, and patients with restrictive lung disease. PLoS ONE, 2017, 12, e0182849.	1.1	9

#	Article	IF	CITATIONS
55	ABT-737, a BH3 Mimetic, Enhances the Therapeutic Effects of Ionizing Radiation in K-ras Mutant Non-Small Cell Lung Cancer Preclinical Model. Yonsei Medical Journal, 2022, 63, 16.	0.9	9
56	Comparative Study of Patients in Correct Usage of and Preference for the Swinghaler and Turbuhaler Multidose Inhalers. Journal of Asthma, 2012, 49, 750-756.	0.9	8
57	Clinical significance of GADD153 expression in stage I non-small cell lung cancer. Oncology Letters, 2012, 4, 408-412.	0.8	8
58	Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea. Tuberculosis and Respiratory Diseases, 2017, 80, 52.	0.7	8
59	Whole Blood Interferon-Î <sup>3</sup> Release Assay Is Insufficient for the Diagnosis of Sputum Smear Negative Pulmonary Tuberculosis. Yonsei Medical Journal, 2014, 55, 725.	0.9	7
60	Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea. Translational Lung Cancer Research, 2021, 10, 4353-4367.	1.3	7
61	Indicators and Qualitative Assessment of Lung Cancer Management by Health Insurance Review and Assessment Service (HIRA) of Korea in 2015. Tuberculosis and Respiratory Diseases, 2018, 81, 19.	0.7	6
62	Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation. Cancer Biology and Therapy, 2020, 21, 741-748.	1.5	6
63	Two Cases of Post Transplant Lymphoproliferative Disorder in Lung Transplant Recipients. Korean Journal of Internal Medicine, 2004, 19, 276-281.	0.7	6
64	Early lung carcinogenesis and tumor microenvironment observed by single-cell transcriptome analysis. Translational Oncology, 2022, 15, 101277.	1.7	6
65	Association of Specific Immunoglobulin E to Staphylococcal Enterotoxin with Airway Hyperresponsiveness in Asthma Patients. Tuberculosis and Respiratory Diseases, 2016, 79, 295.	0.7	5
66	Increased number of subclones in lung squamous cell carcinoma elicits overexpression of immune related genes. Translational Lung Cancer Research, 2020, 9, 659-669.	1.3	5
67	Lessons learned from continued TB outbreaks in a high school. PLoS ONE, 2017, 12, e0188076.	1.1	5
68	A Rare Case of Primary Thymic Adenocarcinoma Mimicking Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2015, 78, 112.	0.7	4
69	Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation. Journal of Cancer, 2019, 10, 5549-5556.	1.2	4
70	First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea. Anticancer Research, 2022, 42, 1615-1622.	0.5	4
71	High versus low attenuation thresholds to determine the solid component of ground-glass opacity nodules. PLoS ONE, 2018, 13, e0205490.	1.1	3
72	Safety of endobronchial ultrasoundâ€guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention. Thoracic Cancer, 2018, 9, 1390-1397.	0.8	3

#	Article	IF	CITATIONS
73	Clinical impact of rebiopsy among patients with epidermal growth factor receptorâ€mutant lung adenocarcinoma in a realâ€world clinical setting. Thoracic Cancer, 2021, 12, 890-898.	0.8	3
74	Methionyl-tRNA synthetase and aminoacyl-tRNA synthetases interacting multi-functional protein-lacking exon 2 as potential diagnostic biomarkers for lung cancer. American Journal of Cancer Research, 2021, 11, 3135-3144.	1.4	2
75	Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion before and during cisplatin chemotherapy in patients with intrathoracic malignancy. Tuberculosis and Respiratory Diseases, 1999, 46, 811.	0.2	1
76	A Case of Well-Differentiated Thymic Carcinoma with Extensive Cystic Degeneration. Tuberculosis and Respiratory Diseases, 1999, 46, 718.	0.2	1
77	A Case of Docetaxel Induced Subacute Cutaneous Lupus Erythematosus. Tuberculosis and Respiratory Diseases, 2009, 66, 380.	0.7	1
78	Association of Insulin Receptor Substrate-1 G972R Variant with Non-small Cell Lung Cancer Risk. Tuberculosis and Respiratory Diseases, 2009, 67, 8.	0.7	1
79	A Case of Malignant Rhabdoid Tumor in the Anterior Mediastinum. Tuberculosis and Respiratory Diseases, 2009, 67, 462.	0.7	1
80	An Isoform of the Oncogenic Splice Variant AIMP2-DX2 Detected by a Novel Monoclonal Antibody. Biomolecules, 2020, 10, 820.	1.8	1
81	Is Methionyl-tRNA Synthetase Applicable as a Diagnostic Marker for Lung Cancer in Bronchial Ultrasound-Guided Brushing Cells?. Diagnostics, 2021, 11, 1830.	1.3	1
82	Malignant thoracic lymph node classification with deep convolutional neural networks on real-time endobronchial ultrasound (EBUS) images. Translational Lung Cancer Research, 2022, 11, 14-23.	1.3	1
83	Hippocampal Metastasis Rate Based on Non-Small Lung Cancer TNM Stage and Molecular Markers. Frontiers in Oncology, 2022, 12, .	1.3	1
84	Correlation of Gross Appearance or RBCs Numbers with Pleural Histocytology and Pleural Fluid Carcinoembryonic Antigen Values in Malignancy Associated Pleural Effusions. Tuberculosis and Respiratory Diseases, 1998, 45, 1031.	0.2	0
85	The usefulness of dyspnea rating in evaluation for pulmonary impairment/disability in patients with chronic pulmonary disease. Tuberculosis and Respiratory Diseases, 1999, 46, 204.	0.2	0
86	Comparison of Treadmill and Cycle Ergometer in Male Korean College Students. Tuberculosis and Respiratory Diseases, 1999, 47, 26.	0.2	0
87	A Case of Isolated Right Pulmonary Artery Agenesis. Tuberculosis and Respiratory Diseases, 2004, 57, 489.	0.7	Ο
88	A Case of Primary Pericardial Malignant Mesothelioma. Tuberculosis and Respiratory Diseases, 2004, 57, 599.	0.7	0
89	Alteration of Coagulation and Fibrinolysis System According to Right Ventricular Dysfunction in Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases, 2006, 60, 625.	0.7	0
90	Clinical Features of Patients with Lung Cancer and Upper Aerodigestive Tract Cancer. Tuberculosis and Respiratory Diseases, 2007, 62, 284.	0.7	0

#	Article	IF	CITATIONS
91	A Case of Subungal Abscess and Onycholysis Induced by Docetaxel. Tuberculosis and Respiratory Diseases, 2007, 62, 125.	0.7	0
92	DNA-Damage Inducible 1 is a Property of Human Non-Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2012, 72, 124.	0.7	0
93	Stress Related Cardiomyopathy during Flexible Bronchoscopy. The Korean Journal of Critical Care Medicine, 2013, 28, 127.	0.2	0
94	Biomarkers and diagnostic tools for lung cancer. Journal of the Korean Medical Association, 2021, 64, 66-74.	0.1	0
95	A Study of Microsatellite Instability in Primary Small Cell Lung Cancers by Microsatellite Analysis. Tuberculosis and Respiratory Diseases, 2000, 48, 180.	0.2	0
96	Implication of quantitative culture of bronchoalveolar lavage fluid in the diagnosis of ventilator assocaited pneumonia in patients with antimicrobial therapy. Tuberculosis and Respiratory Diseases, 2000, 49, 72.	0.2	0
97	Clinical Meaning of INNO-LiPA Test in the Diagnosis of Rifampin Resistant Tuberculosis. Tuberculosis and Respiratory Diseases, 2003, 55, 344.	0.2	0
98	Promoter -202 <i>A/C</i> Polymorphism of Insulin-like Growth Factor Binding Protein-3 Gene and Non-small Cell Lung Cancer Risk. Tuberculosis and Respiratory Diseases, 2005, 58, 359.	0.7	0
99	Photodynamic Therapy for Endobronchial Obstruction due to Recurrent Lung Cancer - 2 Cases Report Journal of Lung Cancer, 2007, 6, 35.	0.2	0
100	The Clinical and Pathologic Features according to Expression of Acyl Protein Thioesterase-1 (APT1) in Stage I Non-small Cell Lung Cancer. Tuberculosis and Respiratory Diseases, 2010, 68, 212.	0.7	0
101	A Cerebral Air Embolism after CT-Guided Percutaneous Transthoracic Fine-Needle Aspiration Biopsy of the Lung. Korean Journal of Medicine, 2013, 85, 416.	0.1	0